In vitro activity of rifampicin, rifapentine and rifabutin in combination with their 25-deacetyl-metabolites against various Mycobacterium tuberculosis lineages
Rifamycin metabolites exhibit additive effects with parent drugs, potentially enhancing bactericidal activity. This highlights that rifamycin susceptibility testing should account for both parent drugs and their metabolites, as these metabolites also exhibit antimicrobial activity. Additionally, these findings support further pharmacokinetic/pharmacodynamic studies to optimize TB treatment regimens, particularly in relation to metabolite-to-parent drug ratios in patients.
Authors
- Charlotte Genestet (ORCID: https://orcid.org/0000-0001-6846-4053)
- Olivier Bahuaud (ORCID: https://orcid.org/0000-0002-1015-6987)
- Oana Dumitrescu (ORCID: https://orcid.org/0000-0001-8193-1437)
- Elisabeth Hodille (ORCID: https://orcid.org/0000-0002-5144-1987)
- Florence Ader (ORCID: https://orcid.org/0000-0002-4778-4338)
- Sylvain Goutelle (ORCID: https://orcid.org/0000-0002-1853-2932)
- Chloé Bourg
Institutions
- Université Claude Bernard Lyon 1 (FR)
- École Normale Supérieure de Lyon (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Hospices Civils de Lyon (FR)
- Laboratoire de Biométrie et Biologie Evolutive (FR)
- Centre International de Recherche en Infectiologie (FR)
Publication Details
- Journal
- Annals of Clinical Microbiology and Antimicrobials
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1186/s12941-025-00784-w
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Agence Nationale de la Recherche